TNGX Stock Forecast 2025-2026
Distance to TNGX Price Targets
TNGX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Tango Therapeutics (TNGX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TNGX and similar high-potential opportunities.
Latest TNGX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, TNGX has a bullish consensus with a median price target of $11.50 (ranging from $8.00 to $16.00). Currently trading at $1.64, the median forecast implies a 601.2% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yuan Zhi at B. Riley Securities, projecting a 875.6% upside. Conversely, the most conservative target is provided by Yuan Zhi at B. Riley Securities, suggesting a 387.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNGX Analyst Ratings
TNGX Price Target Range
Latest TNGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 5, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Nov 11, 2024 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $8.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Nov 7, 2024 | Guggenheim | Charles Zhu | Buy | Maintains | $8.00 |
| Oct 28, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Sep 10, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Aug 8, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $13.00 |
| Jul 17, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $19.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Jul 9, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| May 28, 2024 | HC Wainwright& Co. | Buy | Maintains | $0.00 | |
| May 28, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $13.00 |
| May 24, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $13.00 |
| May 24, 2024 | Guggenheim | Charles Zhu | Buy | Maintains | $14.00 |
| May 23, 2024 | Wedbush | Robert Driscoll | Outperform | Maintains | $11.00 |
| May 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $17.00 |
| Apr 4, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $17.00 |
| Feb 12, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $18.00 |
| Dec 8, 2023 | B. Riley Securities | Yuan Zhi | Buy | Initiates | $16.00 |
Tango Therapeutics Inc. (TNGX) Competitors
The following stocks are similar to Tango Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tango Therapeutics Inc. (TNGX) Financial Data
Tango Therapeutics Inc. has a market capitalization of $188.11M with a P/E ratio of 0.0x. The company generates $42.07M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -24.2% quarter-over-quarter, while maintaining an operating margin of -993.7% and return on equity of -57.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Tango Therapeutics Inc. (TNGX) Business Model
About Tango Therapeutics Inc.
Develops precision cancer medicines using synthetic lethality.
Tango Therapeutics generates revenue by discovering and developing innovative cancer therapies that target specific genetic vulnerabilities in cancer cells. Their approach focuses on leveraging advancements in genomics and bioinformatics to create personalized treatment options, which can be monetized through partnerships, licensing agreements, and potentially through the commercialization of their drug candidates.
As a leader in precision oncology, Tango Therapeutics is positioned to impact the cancer treatment landscape significantly. Their commitment to uncovering personalized medicine solutions aligns with the increasing demand for targeted therapies, which may enhance patient outcomes and offer new avenues for investment in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
155
CEO
Dr. Barbara L. Weber M.D.
Country
United States
IPO Year
2020
Website
www.tangotx.comTango Therapeutics Inc. (TNGX) Latest News & Analysis
Tango Therapeutics' TNG462 received Orphan Drug Designation for pancreatic cancer. The FDA cleared IND for TNG456, with Phase 1/2 trials starting in 1H 2025. Cash reserves are $258M, funding into 3Q 2026.
Tango Therapeutics' orphan drug designation and IND clearance for TNG456 signal potential breakthroughs in cancer treatment, while strong cash reserves ensure ongoing operations and development.
Tango Therapeutics (TNGX) reported a quarterly loss of $0.35 per share, exceeding the Zacks estimate of $0.32, and a year-over-year increase from a loss of $0.32 per share.
Tango Therapeutics' larger-than-expected quarterly loss signals potential operational challenges, which may concern investors about future profitability and stock performance.
Tango Therapeutics (NASDAQ: TNGX) CEO Barbara Weber will speak at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025, at 10:00 AM ET.
Tango Therapeutics' participation in a prominent biotechnology conference highlights investor interest and potential insights into its cancer therapies, possibly influencing stock performance.
Tango Therapeutics: Chance For A Short Squeeze
2 months agoTango Therapeutics, partnered with Gilead Sciences, may experience a short squeeze due to high short interest and low shares outstanding, potentially boosting TNGX's share price amid recent institutional selling.
High short interest and low shares outstanding in Tango Therapeutics may trigger a short squeeze, potentially boosting TNGX's share price amid institutional selling and positive call option trends.
Tango Therapeutics granted a new employee a stock option for 187,500 shares and 31,250 RSUs, effective December 2, 2024, under its 2023 Inducement plan.
The granting of stock options and RSUs signals potential growth and talent acquisition at Tango Therapeutics, which could enhance its innovation and market position in cancer therapies.
Tango Therapeutics (NASDAQ: TNGX) will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 1:30 PM ET. A live webcast will be accessible.
Tango Therapeutics' presentation at a major healthcare conference could signal upcoming developments in their cancer treatments, impacting stock performance and investor sentiment.
Frequently Asked Questions About TNGX Stock
What is Tango Therapeutics Inc.'s (TNGX) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Tango Therapeutics Inc. (TNGX) has a median price target of $11.50. The highest price target is $16.00 and the lowest is $8.00.
Is TNGX stock a good investment in 2025?
According to current analyst ratings, TNGX has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNGX stock?
Wall Street analysts predict TNGX stock could reach $11.50 in the next 12 months. This represents a 601.2% increase from the current price of $1.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tango Therapeutics Inc.'s business model?
Tango Therapeutics generates revenue by discovering and developing innovative cancer therapies that target specific genetic vulnerabilities in cancer cells. Their approach focuses on leveraging advancements in genomics and bioinformatics to create personalized treatment options, which can be monetized through partnerships, licensing agreements, and potentially through the commercialization of their drug candidates.
What is the highest forecasted price for TNGX Tango Therapeutics Inc.?
The highest price target for TNGX is $16.00 from Yuan Zhi at B. Riley Securities, which represents a 875.6% increase from the current price of $1.64.
What is the lowest forecasted price for TNGX Tango Therapeutics Inc.?
The lowest price target for TNGX is $8.00 from Yuan Zhi at B. Riley Securities, which represents a 387.8% increase from the current price of $1.64.
What is the overall TNGX consensus from analysts for Tango Therapeutics Inc.?
The overall analyst consensus for TNGX is bullish. Out of 10 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are TNGX stock price projections?
Stock price projections, including those for Tango Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
